ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Rifaximin

Also written as “Rifaximin 200 mg Tablet”, “Low Dose Rifaximin ER” and “High Dose Rifaximin ER”.

Its studies are mostly in Diarrhea · Hepatic Encephalopathy · Rosacea · Anemia, Sickle Cell · Crohn Disease, led by 4 companies.

Drug pageRifaximin: every studyAll 150 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Apr 16, 201322 company-led studies, 1 open or runningNext primary completion: Apr 20, 2027 (phase 4)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bausch Health Companies161 open or runningphase 4since Apr 16, 2013Dec 22, 2005Apr 20, 2027phase 4 · NCT07285785
Alfasigmaits history only40 open or runningphase 2since Feb 19, 2015Feb 19, 2015none ahead
Novartisits history only10 open or runningphase 3since Sep 29, 2016Sep 29, 2016none ahead
Teva Pharmaceutical Industriesits history only10 open or runningphase 3since Jul 9, 2015Jul 9, 2015none ahead

Also a collaborator on its studies: bioRASI, Cromsource and Parexel.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Bausch Health Companies only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2005First study: phase 2 study in Irritable Bowel SyndromeFirst studyNCT00269412 · 525 enrolled · United States
  2. Dec 22, 2005Phase 3 study in Clostridium InfectionsNCT00269399 · 237 enrolled · United States
  3. Feb 28, 2006Phase 3 study in Hepatic EncephalopathyNCT00298038 · 299 enrolled
  4. May 17, 2006Phase 3 study in DiarrheaNCT00328380 · 660 enrolled · United States
  5. May 27, 2008Phase 3 study in Hepatic EncephalopathyNCT00686920 · 322 enrolled · United States, Canada
  6. Jul 16, 20082 phase 3 studiesNCT00731679, NCT00724126
  7. Aug 24, 2008Phase 3 study in DiarrheaNCT00742469 · 210 enrolled · Mexico
  8. Aug 27, 2008Phase 1 study in PharmacokineticNCT00743912 · 24 enrolled
  9. Feb 27, 2012Phase 3 study in DiarrheaNCT01543178 · 2,583 enrolled · United States, Germany, United Kingdom
  10. Apr 16, 20132 phase 4 studies in Hepatic EncephalopathyNCT01842581, NCT01846663
  11. Jul 17, 2013Phase 2 study in Liver CirrhosisNCT01904409 · 420 enrolled · United States, Russian Federation
  12. Jan 22, 2019Phase 4 study in Severe Hepatic ImpairmentNCT03818672 · 5 enrolled · United States
  13. Oct 18, 2021Phase 2 study in Anemia, Sickle CellNCT05098028 · 44 enrolled · United States, Canada, Kenya
  14. Dec 2, 2025Phase 4 study in DiarrheaNCT07285785 · 54 planned · United States

Ahead

  1. Apr 20, 2027Primary completion: phase 4 study in DiarrheaNCT07285785

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“Bacterial DNA-directed RNA polymerase inhibitor”ChEMBL 37, by rule

Studies

All 16 Bausch Health Companies leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07285785Diarrhea · United States4RecruitingApr 20, 202754
NCT05098028Anemia, Sickle Cell · United States, Canada, Kenya2CompletedSep 4, 202344
NCT03818672Severe Hepatic Impairment · United States4TerminatedFeb 2, 20205
NCT01904409Liver Cirrhosis · United States, Russian Federation2CompletedJun 2015420
NCT01846663Hepatic Encephalopathy · United States4TerminatedFeb 22, 20166
NCT01842581Hepatic Encephalopathy · United States4CompletedDec 17, 2014222
NCT01543178Diarrhea · United States, Germany, United Kingdom3CompletedJun 20142,583
NCT00743912Pharmacokinetic1CompletedOct 200824
NCT00742469Diarrhea · Mexico3CompletedSep 2005210
NCT00724126Diarrhea · United States3CompletedAug 2009637
NCT00731679Abdominal Pain · United States, Canada3CompletedAug 2009623
NCT00686920Hepatic Encephalopathy · United States, Canada3CompletedDec 8, 2010322
NCT00328380Diarrhea · United States3CompletedDec 2006660
NCT00298038Hepatic Encephalopathy3CompletedAug 15, 2008299
NCT00269412Irritable Bowel Syndrome · United States2CompletedAug 2007525
NCT00269399Clostridium Infections · United States3CompletedDec 2008237

How it is read

Names in the registry

  • “Rifaximin”, 12 entries
  • “Rifaximin 200 mg Tablet”, 1 entry
  • “Low Dose Rifaximin ER”, 1 entry
  • “High Dose Rifaximin ER”, 1 entry
  • “Rifaximin delayed release tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.